Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"factor IX"”.
-
Novel carriers for oral delivery of hemophiliac factor IX
… characterized by the deficiency of coagulation factor IX (FIX), rely on injection-based administration that cause pain and discomfort, leading to noncompliance and risk of subsequent bleeding episodes. A non-invasive protein replacement therapy using an oral delivery system can both overcome …
-
Characterization of Post-translational Modifications and Resulting Structure/Function Relationships of Recombinant Human Factor IX Produced in the Milk of Transgenic Pigs
… caused by a deficiency in or dysfunction of factor IX (FIX), a complex plasma glycoprotein required for the formation and maintenance of blood clots. Treatment of hemophilia B involves infusion of replacement FIX currently derived from two sources: FIX purified from pools of human plasma …
-
An integrated process for the recovery of clinically significant trace proteins from human plasma
Methods for the preparation of concentrates of factor VIII, factor IX, high purity factor IX, Cl esterase inhibitor, specific immunoglobulin and platelet factor XIII are described. These procedures were developed or modified with the aim of integration into an automated process that would allow …
-
Upstream and downstream issues in the production of recombinant vitamin K-dependent proteins in the milk of transgenic pigs
… therapeutic proteins, such as protein C and Factor IX, have spurred the development of recombinant DNA technology for large-scale, economically feasible production of therapeutic proteins. The mammary gland is unique in its ability to synthesize and secrete large amounts of protein into a …
-
Improving the Safety and Efficacy of AAV Gene Therapy for Hemophilia A
… We hypothesized that selective pressures keep factor VIII (FVIII) activity low. Using criteria established from studies of factor IX-Padua, a factor IX transgene with increased specific activity, we identified 52 amino acids we hypothesized would lead to increased FVIII activity when …
-
In Vitro Binding and Transport Regulation by Endothelial Cells: Preliminary Studies looking at FIX and IGF-I
… study investigates how the recombinant source of Factor IX (FIX), a blood coagulant protein used in the treatment of Hemophilia B, impacts surface ligand binding (FIX to its specific receptors) to bovine aortic endothelial cells (BAECs). Competitive binding experiments between 125I-FIX and FIX …
-
Characterisation of the potentially diverse transcriptional regulatory mechanisms of human coagulation PZ gene.
… in two evolutionarily related proteins, human factor IX and protein C. These regions were found to be bound specifically by potentially the same or a similar protein; but the identity of the protein could not be confirmed as either PEA3 or Ets1, although transactivation data from HepG2 cells …
-
Evaluation of the determinants and characterization of bleeding in hemophilia A and B carriers
… disorders caused by a deficiency in coagulation factor VIII (FVIII) or coagulation factor IX (FIX), respectively. Due to the X-linked inheritance pattern, males are affected with the disease, while females are almost exclusively carriers of hemophilia. Although carriers were historically assumed …
-
In Vivo Genome Editing: Proof of Concept in Neonatal and Adult Mouse Liver
… to drive robust expression of clotting factor IX, deficient in hemophilia B, and correct the disease phenotype in mice treated as adults. This approach was adapted to create a general platform for liver-directed protein replacement therapy. Using ZFNs targeting the mouse albumin locus, …
-
Physcomitrella patens (Hedw.) B.S.G. als Bioreaktor : Proteinzielsteuerung und Produktion von rekombinantem humanem Blutgerinnungsfaktor IX
… des komplexen Blutgerrinungsproteins Faktor IX die Leistungsfähigkeit des Systems unter Beweis gestellt. Methodischen Vorarbeiten an Faktor IX-transgenen Pflanzen folgte die Erstellung einer zweiten, dreifach transgenen Moosgeneration. Diese Linien wurden, abgesehen von Faktor IX, noch mit …
-
Physcomitrella patens (Hedw.) B.S.G. als Bioreaktor : quantitative Promotoranalyse und Produktion eines komplexen humanen Blutgerinnungsfaktors
… können. <br>Der humane Blutgerinnungsfaktor IX wurde als Modellprotein zur Optimierung von Physcomitrella patens als Produktionsplattform für komplexe rekombinante Proteine ausgewählt. Um die Produktion eines biologisch aktiven Faktor IX zu gewährleisten, sind stabile transgene Pflanzen …